The anti-CCR5 therapeutic antibody maraviroc blocks the HRS-mediated recruitment of monocytes, thus decreasing the number of TAM within the cHL microenvironment and curtailing tumor growth in cHL mouse models (35). The gene discussed is CCR5; the disease is classic Hodgkin lymphoma.